

Form for Nominating Substances for 2011 IRIS Agenda

This is a fill-and-print form. This form cannot be saved. All forms and other correspondence submitted in response to the IRIS nomination request will be placed on the public docket. Please submit your nominations and comments, identified by Docket ID No. EPA-HQ-ORD-2010-0744, by one of the following methods:

<http://www.regulations.gov>: Follow the on-line instructions for submitting comments.

e-Mail: ORD.Docket@epa.gov.

Fax: (202) 566-9744.

Mail: Office of Environmental Information (OEI) Docket (Mail Code: 2822T), U.S.

Environmental Protection Agency, 1200 Pennsylvania Ave., NW, Washington, DC 20460.

The phone number is (202) 566-1752.

Hand Delivery: The OEI Docket is located in the EPA Headquarters Docket Center, EPA West Building, Room 3334, 1301 Constitution Ave., NW, Washington, DC. The EPA Docket Center Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Eastern Time, Monday through Friday, excluding federal holidays. The phone number is (202) 566-1752.

Nominator's name:

Title:

Affiliation:

Telephone No.:

Address:

e-mail address:

Chemical Substance Name:

Common Synonym(s), if any:

CAS No.:

Information for Prioritizing Nominations

1. What is the potential public health impact for this chemical?

2. Is this assessment needed to fulfill a chemical-specific EPA mandate or program need (e.g., statutory, regulatory, or court-ordered deadline)? Please describe the mandate or program need. When is the assessment needed?

3. Is this assessment a priority for stakeholders outside of EPA (e.g., states, tribes, local governments, environmental organizations, industries, or other IRIS users)? Why is it a priority?

4. Are you aware of other assessments of this substance that may be available to EPA (e.g., an EPA program has assessed this substance, but it has not received Agency-wide IRIS review, a state or other federal agency has an assessment, or another government or private organization has assessed this substance)? If possible, please provide specific information to allow ORD to locate and obtain the assessment.

5. For substances being nominated for IRIS *reassessment*, what, if any, significant new scientific data or risk assessment methodology is available that you believe would be likely to appreciably change the existing IRIS assessment? Please provide specific citations and other information that would allow EPA to locate and obtain the papers or data.

6. Are you aware of other factors that would make this substance a priority for IRIS assessment (e.g., widespread exposure, expected toxicity, or potentially susceptible populations)?